2018
Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States
Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Research And Treatment 2018, 168: 727-737. PMID: 29332137, DOI: 10.1007/s10549-018-4659-4.Peer-Reviewed Original ResearchConceptsInitial systemic therapyMetastatic breast cancerSystemic therapyBreast cancerDe novo metastatic breast cancerNovo metastatic breast cancerEarly-stage breast cancerHuman epidermal receptor 2HR-positive patientsInitial systemic treatmentGuideline-concordant careHER2-positive patientsFirst-line therapyTriple-negative tumorsPatterns of careQuality of careGuideline concordanceInitial therapyMBC cohortUntreated patientsElderly patientsMost patientsSystemic treatmentInitial treatmentHospice utilization
2013
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. The Breast 2013, 22: 525-531. PMID: 23352568, PMCID: PMC3713786, DOI: 10.1016/j.breast.2012.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCentral Nervous System NeoplasmsCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMiddle AgedPractice Patterns, Physicians'PrognosisProportional Hazards ModelsReceptor, ErbB-2Retrospective StudiesTrastuzumabTreatment OutcomeConceptsHER2-positive metastatic breast cancerMetastatic breast cancerMedian overall survivalTrastuzumab-based therapyOverall survivalHazard ratioMedian durationBreast cancerCox proportional hazards modelCentral nervous system diseasePost-trastuzumab eraTreatment practice patternsHER2-positive patientsKaplan-Meier methodologyLog-rank testPatterns of careLine of treatmentNervous system diseasesProportional hazards modelTime of deathCNS metastasesCNS progressionMetastatic settingFirst recurrenceShorter OS
2009
Racial Differences in Definitive Breast Cancer Therapy in Older Women
Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial Differences in Definitive Breast Cancer Therapy in Older Women. Medical Care 2009, 47: 765-773. PMID: 19536008, DOI: 10.1097/mlr.0b013e31819e1fe7.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBlack or African AmericanBreast NeoplasmsChi-Square DistributionFemaleHealth Services ResearchHealthcare DisparitiesHospitalsHumansLogistic ModelsMastectomyMedicareMultivariate AnalysisPractice Patterns, Physicians'Quality of Health CareSEER ProgramSensitivity and SpecificitySocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-volume hospitalsDefinitive primary therapyHigh-quality hospitalsBreast-conserving surgeryBreast cancer therapyBreast cancerPrimary therapyWhite womenRacial disparitiesStage I/II breast cancerBlack womenPrimary breast cancer therapyEarly-stage breast cancerLow-volume hospitalsBreast cancer patientsBreast cancer surgeryPatterns of careSEER-Medicare databaseCancer therapyPopulation-based sampleOlder Black womenDefinitive therapyVolume hospitalsCancer surgeryCancer patients